Independent Evidence Review Affirms Flu, RSV, and COVID-19 Protection for Infants and Children

BackgroundAs the 2026-27 respiratory virus season begins, parents of infants and young children face the usual questions about protecting against influenza, RSV, and COVID-19. What is different this year is the source of the guidance. The CDC’s Advisory Committee on Immunization Practices (ACIP) has been disrupted since 2025, with members replaced and no restored expert-led process as of early October 2026. In response, the Vaccine Integrity Project (based at the University of Minnesota’s CIDRAP) partnered with the American Medical Association to conduct an independent evidence review of newly published studies. That review informed coordinated recommendations from the American Academy of Pediatrics (AAP), American Academy of Family Physicians (AAFP), American College of Obstetricians and Gynecologists (ACOG), and Infectious Diseases Society of America (IDSA).The review screened nearly 19,000 studies published since August 2025 and included hundreds that met criteria: 69 for influenza, 155 for COVID-19, and 75 for RSV. It focused on effectiveness against severe outcomes and safety signals relevant to infants, children, pregnant people, and other groups.

What ChangedThe core findings for parents of babies and toddlers are reassuring and consistent with prior seasons:

1. **Influenza**: Across eight surveillance seasons, vaccination was 80% effective against laboratory-confirmed influenza-associated death in children ages 6 months to 17 years. For children with underlying conditions, effectiveness against hospitalization or ED visits was 48%. Maternal vaccination reduced symptomatic disease in infants under 6 months by about 44%.
2. **COVID-19**: Maternal vaccination reduced ED/urgent care visits in pregnant people by 58% and cut hospital contacts in infants during the first two months of life by 50–54%. Among children 9 months to 4 years, vaccination was associated with a 76% reduction in COVID-related ED visits.
3. **RSV**: Maternal RSV vaccination (Abrysvo) reduced infant hospitalization risk by 51–70%. The long-acting monoclonal antibody nirsevimab reduced RSV hospitalization by 63.6–93% in the first season, regardless of timing. No comparative study linked maternal RSV vaccination to preterm birth or other adverse pregnancy outcomes. AAP also expanded high-risk criteria for second-season protection in children 8–19 months.No new pediatric safety signals were identified in comparative studies. Professional societies continue to recommend:
4. Flu vaccine for all children 6 months and older.
5. RSV protection for all infants under 8 months entering their first season (via maternal vaccine or infant antibody) and expanded eligibility for certain higher-risk children in a second season.
6. COVID-19 vaccine routinely for infants and children 6–23 months, with risk-based or optional approaches for older children, and vaccination during pregnancy.ACOG extended the maternal RSV vaccine window to March 1 (from January 31), reflecting later and more severe recent seasons.

Competing ViewpointsOne perspective holds that independent society recommendations, grounded in a transparent literature review outside the disrupted federal process, restore a reliable evidence base for clinicians and families when federal guidance is delayed or contested. Supporters note that the findings align with previous high-quality data and that medical organizations have long issued specialty-specific advice.Another viewpoint argues that diverging from CDC/ACIP processes risks confusion for parents and that only federal recommendations should drive public programs, insurance coverage, and school requirements. Some critics of the independent process question the selection of studies or the timing, while others point to ongoing debates about COVID-19 dosing in low-risk older children or the precise duration of RSV antibody protection. Public health officials in some states continue to reference both federal and society guidance, and coverage decisions can differ.Parents may encounter clinics following AAP/ACOG schedules, others still citing last year’s CDC language, and online sources amplifying either “vaccines work as before” or “guidance is fragmented.”

What to Watch Next

1. **Clinic conversations this week**: Ask your pediatrician or obstetrician which schedule they are using and whether your infant is eligible for nirsevimab (or if you are still pregnant, for Abrysvo). Confirm flu vaccine availability for household members who are old enough.
2. **Second-season RSV**: Children 8–19 months with certain conditions may now qualify; check the updated AAP criteria if your child had a first-season dose or maternal protection last year.
3. **Coverage and access**: Watch whether state programs, insurance, and pharmacies update forms to match the society recommendations or remain tied to federal language.
4. **Surveillance**: Early RSV activity has been noted in some regions; flu and COVID trends will clarify over the next weeks. The Vaccine Integrity Project site and society pages offer the underlying studies.
5. **Related outbreaks**: The ongoing measles resurgence (Pennsylvania at 1,222 cases as of mid-October, with a sixth associated death under state review) underscores the broader value of routine childhood vaccines, even as respiratory season tools remain available.For the full evidence summaries, see the Vaccine Integrity Project 2026-27 respiratory season page and the JAMA-published reviews that supported the society recommendations. Talk with your child’s clinician about the specific products and timing that fit your family.*Sources include the Vaccine Integrity Project/AMA evidence review, AAP, AAFP, ACOG, and IDSA 2026-27 recommendations, and contemporary pediatric reporting as of 15 October 2026.*